These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 26711311

  • 1. Indirect assessment of neutralizing anti-drug antibodies utilizing pharmacokinetic assay data.
    Vettermann C, Ortiz J, Lee S, Sanchez S, Victor HP, Ma M, Heath T, Gupta S.
    J Immunol Methods; 2016 Feb; 429():28-38. PubMed ID: 26711311
    [Abstract] [Full Text] [Related]

  • 2. Comparison of cell-based and non-cell-based assay platforms for the detection of clinically relevant anti-drug neutralizing antibodies for immunogenicity assessment of therapeutic proteins.
    Hu J, Wala I, Han H, Nagatani J, Barger T, Civoli F, Kaliyaperumal A, Zhuang Y, Gupta S.
    J Immunol Methods; 2015 Apr; 419():1-8. PubMed ID: 25795420
    [Abstract] [Full Text] [Related]

  • 3. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics.
    Coddens A, Snoeck V, Bontinck L, Buyse MA, Pine SO.
    J Immunol Methods; 2020 Dec; 487():112896. PubMed ID: 33065122
    [Abstract] [Full Text] [Related]

  • 4. Drug Target Interference in Immunogenicity Assays: Recommendations and Mitigation Strategies.
    Zhong ZD, Clements-Egan A, Gorovits B, Maia M, Sumner G, Theobald V, Wu Y, Rajadhyaksha M.
    AAPS J; 2017 Nov; 19(6):1564-1575. PubMed ID: 29063411
    [Abstract] [Full Text] [Related]

  • 5. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
    Schneider AK, Vainshtein I, Roskos LK, Chavez C, Sun B, Liang M.
    J Immunol Methods; 2016 Aug; 435():68-76. PubMed ID: 27220271
    [Abstract] [Full Text] [Related]

  • 6. Assay development considerations to improve drug tolerance in direct competitive ligand binding neutralizing antibody assays, pretreatment strategies.
    Rathi A, Rinker S, Niu H, Carter C, Kumar S, Cowan K.
    J Immunol Methods; 2023 Jun; 517():113484. PubMed ID: 37116778
    [Abstract] [Full Text] [Related]

  • 7. Development and characterization of a pre-treatment procedure to eliminate human monoclonal antibody therapeutic drug and matrix interference in cell-based functional neutralizing antibody assays.
    Xu W, Jiang H, Titsch C, Haulenbeek JR, Pillutla RC, Aubry AF, DeSilva BS, Arnold ME, Zeng J, Dodge RW.
    J Immunol Methods; 2015 Jan; 416():94-104. PubMed ID: 25445325
    [Abstract] [Full Text] [Related]

  • 8. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics.
    Finco D, Baltrukonis D, Clements-Egan A, Delaria K, Gunn GR, Lowe J, Maia M, Wong T.
    J Pharm Biomed Anal; 2011 Jan 25; 54(2):351-8. PubMed ID: 20863644
    [Abstract] [Full Text] [Related]

  • 9. Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples.
    Cludts I, Meager A, Thorpe R, Wadhwa M.
    J Immunol Methods; 2013 Sep 30; 395(1-2):37-44. PubMed ID: 23831137
    [Abstract] [Full Text] [Related]

  • 10. Development of an enzymatic assay for the detection of neutralizing antibodies against therapeutic angiotensin-converting enzyme 2 (ACE2).
    Liao K, Sikkema D, Wang C, Lee TN.
    J Immunol Methods; 2013 Mar 29; 389(1-2):52-60. PubMed ID: 23298658
    [Abstract] [Full Text] [Related]

  • 11. Approaches to improve drug tolerance and target tolerance in the assessment of neutralizing anti-drug antibodies.
    Wu B, Schnarr M, Devlin JL, Brown S, Yang TY.
    Bioanalysis; 2019 Nov 29; 11(22):2061-2074. PubMed ID: 31829737
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
    Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, Malucchi S, Mehling M, Montalban X, Polman CH, Rudzki D, Schautzer F, Sellebjerg F, Sørensen PS, Deisenhammer F.
    Mult Scler; 2014 Apr 29; 20(5):577-87. PubMed ID: 24009164
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Drug Removal Strategies in Competitive Ligand Binding Neutralizing Antibody (NAb) Assays: Highly Drug-Tolerant Methods and Interpreting Immunogenicity Data.
    Partridge MA, Karayusuf EK, Shyu G, Georgaros C, Torri A, Sumner G.
    AAPS J; 2020 Aug 17; 22(5):112. PubMed ID: 32808205
    [Abstract] [Full Text] [Related]

  • 16. Strategies to Determine Assay Format for the Assessment of Neutralizing Antibody Responses to Biotherapeutics.
    Wu B, Chung S, Jiang XR, McNally J, Pedras-Vasconcelos J, Pillutla R, White JT, Xu Y, Gupta S.
    AAPS J; 2016 Nov 17; 18(6):1335-1350. PubMed ID: 27495119
    [Abstract] [Full Text] [Related]

  • 17. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics.
    Gupta S, Devanarayan V, Finco D, Gunn GR, Kirshner S, Richards S, Rup B, Song A, Subramanyam M.
    J Pharm Biomed Anal; 2011 Jul 15; 55(5):878-88. PubMed ID: 21531522
    [Abstract] [Full Text] [Related]

  • 18. Identification and elimination of target-related matrix interference in a neutralizing anti-drug antibody assay.
    Schwickart M, Mehrzai F, Pearson J, Shaghasi N, Chavez C, Schneider A, Wu S, Roskos L, Liang M.
    J Immunol Methods; 2014 Jan 31; 403(1-2):52-61. PubMed ID: 24287421
    [Abstract] [Full Text] [Related]

  • 19. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays.
    Zoghbi J, Xu Y, Grabert R, Theobald V, Richards S.
    J Immunol Methods; 2015 Nov 31; 426():62-9. PubMed ID: 26255760
    [Abstract] [Full Text] [Related]

  • 20. Interference in a Neutralizing Antibody Assay for Odronextamab, a CD20xCD3 Bispecific mAb, from Prior Rituximab Therapy and Possible Mitigation Strategy.
    Irvin SC, D'Orvilliers A, Bloch N, Boccio K, Pennucci J, Brouwer-Visser J, Ullman E, Rajadhyaksha M, Hassanein M, Potocky T, Torri A, Hermann A, Partridge MA.
    AAPS J; 2022 Jun 21; 24(4):76. PubMed ID: 35725847
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.